William S Kloetzer

Title: William S Kloetzer: Innovator in Monoclonal Antibodies

Introduction

William S Kloetzer is a prominent inventor based in Carlsbad, CA (US). He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. With a total of 8 patents to his name, Kloetzer's work has had a profound impact on therapeutic applications.

Latest Patents

Kloetzer's latest patents include the development of gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies. These antibodies specifically bind to human CD23, the low affinity receptor for IgE (FceRII/CD23). The patents disclose methods for modulating or inhibiting induced IgE expression, which is crucial for treating various disease conditions. The antibodies have practical utility in the treatment or prophylaxis of allergic conditions, autoimmune diseases, and inflammatory diseases. Additionally, methods for inhibiting the production of IgE in human subjects with IgE-mediated allergic disorders by administering anti-CD23 antibodies are also covered in his patents.

Career Highlights

Throughout his career, Kloetzer has worked with notable companies such as Biogen Idec, Inc. and Biogen Idec Ma Inc. His experience in these organizations has allowed him to refine his expertise in the field of monoclonal antibodies and their therapeutic applications.

Collaborations

Kloetzer has collaborated with esteemed colleagues, including Mitchell E Reff and Takehiko Nakamura. These collaborations have further enhanced his research and development efforts in the biotechnology sector.

Conclusion

William S Kloetzer's innovative work in monoclonal antibodies has paved the way for advancements in therapeutic treatments for various diseases. His contributions continue to influence the field of biotechnology and improve patient outcomes.